| abstract |
The present invention relates to (a) a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable salt thereof, for administration simultaneously, individually or sequentially to treat a proliferative disease, in particular a c-Met dependent proliferative disease, and (b ) A pharmaceutical combination comprising one or more c-Met receptor tyrosine kinase inhibitors or a pharmaceutically acceptable salt thereof; Pharmaceutical compositions comprising such combinations; A method of treating a subject having a proliferative disease comprising administering the combination to a subject in need thereof; It relates to the use of such a combination for the treatment of proliferative diseases. |